BridgeBio Oncology Therapeutics (BBOT) Non-Interest Income (2024 - 2025)
BridgeBio Oncology Therapeutics (BBOT) posted Non-Interest Income of $1159.0 for Q2 2025, down 52.6% sequentially from $2445.0 in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Non-Interest Income (2024 - 2025) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Non-Interest Income for 2 years, with the latest figure at $1159.0 in Q2 2025.
- Quarterly Non-Interest Income changed N/A year-over-year to $1159.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $1159.0 (down 86.57% YoY) and the FY2024 annual result came in at $6182.0, changed N/A from the prior year.
- Non-Interest Income retreated to $1159.0 in Q2 2025 per BBOT's latest filing, from $2445.0 in the prior quarter.
- Over five years, Non-Interest Income peaked at $3182.0 in Q4 2024 and troughed at $1159.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Interest Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1,159.00 |
| Mar 31, 2025 | 2,445.00 |
| Dec 31, 2024 | 3,182.00 |
| Sep 30, 2024 | 3,000.00 |